CL2022001743A1 - Dosis de gamma-hidroxibutirato (ghb) - Google Patents

Dosis de gamma-hidroxibutirato (ghb)

Info

Publication number
CL2022001743A1
CL2022001743A1 CL2022001743A CL2022001743A CL2022001743A1 CL 2022001743 A1 CL2022001743 A1 CL 2022001743A1 CL 2022001743 A CL2022001743 A CL 2022001743A CL 2022001743 A CL2022001743 A CL 2022001743A CL 2022001743 A1 CL2022001743 A1 CL 2022001743A1
Authority
CL
Chile
Prior art keywords
ghb
hydroxybutyrate
gamma
dosage
narcolepsy
Prior art date
Application number
CL2022001743A
Other languages
English (en)
Spanish (es)
Inventor
Skobieranda Franck
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of CL2022001743A1 publication Critical patent/CL2022001743A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
CL2022001743A 2019-12-24 2022-06-24 Dosis de gamma-hidroxibutirato (ghb) CL2022001743A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962953288P 2019-12-24 2019-12-24
US202062993372P 2020-03-23 2020-03-23
US202063000547P 2020-03-27 2020-03-27
US202063052676P 2020-07-16 2020-07-16

Publications (1)

Publication Number Publication Date
CL2022001743A1 true CL2022001743A1 (es) 2023-02-10

Family

ID=74191949

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001743A CL2022001743A1 (es) 2019-12-24 2022-06-24 Dosis de gamma-hidroxibutirato (ghb)

Country Status (14)

Country Link
US (3) US20210186907A1 (cg-RX-API-DMAC7.html)
EP (1) EP4081204A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023508975A (cg-RX-API-DMAC7.html)
KR (1) KR20220119429A (cg-RX-API-DMAC7.html)
CN (1) CN115209885A (cg-RX-API-DMAC7.html)
AU (1) AU2020414694A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022012594A2 (cg-RX-API-DMAC7.html)
CA (1) CA3162974A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022001743A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022010330A2 (cg-RX-API-DMAC7.html)
IL (1) IL294176A (cg-RX-API-DMAC7.html)
MX (1) MX2022007968A (cg-RX-API-DMAC7.html)
TW (1) TW202135790A (cg-RX-API-DMAC7.html)
WO (1) WO2021133778A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391660B (es) 2010-03-24 2025-03-21 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
BR112021006027A2 (pt) 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited formulações de fármaco resistente a álcool
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US12582622B2 (en) 2020-10-08 2026-03-24 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038672A2 (en) 1998-12-23 2000-07-06 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
AU2001291173A1 (en) 2000-09-22 2002-04-02 Orphan Medical, Inc. Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
US7610153B2 (en) * 2002-02-13 2009-10-27 Virginia Commonwealth University Multi-drug titration and evaluation
US7668730B2 (en) 2002-12-17 2010-02-23 JPI Commercial, LLC. Sensitive drug distribution system and method
US8771735B2 (en) 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
EP2566462B1 (en) * 2010-05-04 2020-07-08 Jazz Pharmaceuticals Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US9801852B2 (en) 2013-08-30 2017-10-31 Jazz Pharmaceuticals, Inc. Devices and methods for facilitating and controlling use of a medication
US20180263936A1 (en) * 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders

Also Published As

Publication number Publication date
CN115209885A (zh) 2022-10-18
WO2021133778A1 (en) 2021-07-01
BR112022012594A2 (pt) 2022-09-06
MX2022007968A (es) 2022-09-02
TW202135790A (zh) 2021-10-01
US20240285560A1 (en) 2024-08-29
CA3162974A1 (en) 2021-07-01
AU2020414694A1 (en) 2022-08-18
IL294176A (en) 2022-08-01
US20210186907A1 (en) 2021-06-24
US20210361601A1 (en) 2021-11-25
CO2022010330A2 (es) 2022-10-21
EP4081204A1 (en) 2022-11-02
JP2023508975A (ja) 2023-03-06
KR20220119429A (ko) 2022-08-29

Similar Documents

Publication Publication Date Title
CO2022010330A2 (es) Dosificación de gamma-hidroxibutirato (ghb)
CO2026004964A2 (es) Moduladores de kras
CO2021005987A2 (es) Compuestos de anillo fusionado
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
MX2018011012A (es) Formulaciones y dosis de uricasa pegilada.
ECSP23057264A (es) Inhibidores de cdk2 y métodos de uso de los mismos
CO2022007814A2 (es) Ligandos de la pseudoquinasa tyk2
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
CO2021015793A2 (es) Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33
CO2022000481A2 (es) Inhibidores de enzimas
MX2021004566A (es) Compuestos terapeuticos.
EA202191519A1 (ru) Модуляторы trex1
ECSP22044525A (es) Terapia de combinaci?n que comprende un inhibidor de alk2 y un inhibidor de jak2
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
CO2022000270A2 (es) Inhibidores de enzimas
CL2019002583A1 (es) Inhibidores duales de magl y faah.
MX2022013081A (es) Compuestos para el tratamiento de sars.
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
CO2022014499A2 (es) Moduladores de nlrp3
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
CO2022000266A2 (es) Inhibidores de enzimas